Exact Sciences Corporation

NasdaqCM:EXAS 주식 보고서

시가총액: US$9.4b

Exact Sciences 관리

관리 기준 확인 2/4

Exact Sciences CEO는 Kevin Conroy, Apr2009 에 임명되었습니다 의 임기는 15.58 년입니다. 총 연간 보상은 $ 16.12M, 6.5% 로 구성됩니다. 6.5% 급여 및 93.5% 보너스(회사 주식 및 옵션 포함). 는 $ 36.25M 가치에 해당하는 회사 주식의 0.38% 직접 소유합니다. 36.25M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 5.7 년입니다.

주요 정보

Kevin Conroy

최고 경영자

US$16.1m

총 보상

CEO 급여 비율6.5%
CEO 임기15.6yrs
CEO 소유권0.4%
경영진 평균 재임 기간3.8yrs
이사회 평균 재임 기간5.7yrs

최근 관리 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

Nov 10
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

CEO 보상 분석

Kevin Conroy 의 보수는 Exact Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$214m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$16mUS$1m

-US$204m

Sep 30 2023n/an/a

-US$282m

Jun 30 2023n/an/a

-US$432m

Mar 31 2023n/an/a

-US$517m

Dec 31 2022US$14mUS$510k

-US$624m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$735m

Mar 31 2022n/an/a

-US$745m

Dec 31 2021US$15mUS$963k

-US$596m

Sep 30 2021n/an/a

-US$793m

Jun 30 2021n/an/a

-US$829m

Mar 31 2021n/an/a

-US$720m

Dec 31 2020US$20mUS$499k

-US$824m

Sep 30 2020n/an/a

-US$327m

Jun 30 2020n/an/a

-US$165m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$19mUS$792k

-US$213m

Sep 30 2019n/an/a

-US$216m

Jun 30 2019n/an/a

-US$221m

Mar 31 2019n/an/a

-US$219m

Dec 31 2018US$7mUS$696k

-US$175m

Sep 30 2018n/an/a

-US$143m

Jun 30 2018n/an/a

-US$124m

Mar 31 2018n/an/a

-US$119m

Dec 31 2017US$13mUS$633k

-US$114m

보상 대 시장: Kevin 의 총 보상 ($USD 16.12M )은 US 시장( $USD 7.84M ).

보상과 수익: 회사가 수익성이 없는 동안 Kevin 의 보상이 증가했습니다.

CEO

Kevin Conroy (58 yo)

15.6yrs

테뉴어

US$16,119,899

보상

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

리더십 팀

이름위치테뉴어보상소유권
Kevin Conroy
Chairman of The Board & CEO15.6yrsUS$16.12m0.38%
$ 36.2m
Jake Orville
Executive VP & GM of Screeningno dataUS$3.67m0.0084%
$ 792.7k
Brian Baranick
Executive VP & General Manager of Precision Oncologyno dataUS$3.57m0.0071%
$ 673.0k
Aaron Bloomer
Executive Vice President of Financeless than a year데이터 없음데이터 없음
Jorge Garces
Chief Science Officer3.6yrs데이터 없음데이터 없음
Nassar Nizami
Chief Information Officer1.8yrs데이터 없음데이터 없음
Megan Jones
Associate Manager of Investor Relationsno data데이터 없음데이터 없음
Tim Caprez
Chief Compliance Counsel & VP9.8yrs데이터 없음데이터 없음
James Herriott
Senior VP2.8yrs데이터 없음0.0060%
$ 562.7k
Sarah Condella
Executive Vice President of Human Resources7.5yrsUS$2.71m0.042%
$ 4.0m
Graham Lidgard
Emeritus Chief Science Officer3.8yrsUS$4.21m데이터 없음
Ana Hooker
Chief Laboratory Officer9.3yrsUS$3.95m데이터 없음

3.8yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: EXAS 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Kevin Conroy
Chairman of The Board & CEO15.7yrsUS$16.12m0.38%
$ 36.2m
Daniel Levangie
Independent Director14.3yrsUS$408.75k0.015%
$ 1.4m
D. Coward
Director1.9yrsUS$1.47m0.030%
$ 2.8m
Katherine Zanotti
Independent Director15.6yrsUS$406.25k0.038%
$ 3.6m
Michael Barber
Independent Directorless than a year데이터 없음0.0029%
$ 277.1k
Paul Clancy
Independent Director3.7yrsUS$417.75k0.011%
$ 1.0m
Kathleen Sebelius
Independent Director5.7yrsUS$411.75k0.017%
$ 1.6m
Shacey Petrovic
Independent Director4.3yrsUS$401.25k0.012%
$ 1.2m
James Doyle
Lead Independent Director10.3yrsUS$442.75k0.030%
$ 2.8m

5.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: EXAS 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.